

Information for Colorado Prescribers of Prescription Drugs

Conexence (denosumab-bnht)

- The following information is being provided to Colorado prescribers pursuant to Colorado law HB 19-1131.
- The prices listed below represent the Wholesale Acquisition Costs ("WAC") as made available to the public by a third-party publisher. WAC does not reflect discounts, rebates and other reductions in price. The actual price paid by patients may differ and is dependent upon the individual patient's insurance.

Marketed Product	Strength	Container Size	Description	NDC	WAC (Package)	Package Size
CONEXXENCE (denosumab-bnht) injection, for subcutaneous use	60 mg per 1 mL (60 mg per mL)	1 mL (1 mL)	Prefilled Syringe	65219-668-01	\$1,819.17	1 Box of 1 Prefilled Syringe

Date: **December 22, 2025**

CONEXXENCE (denosumab-bnht) is biosimilar* to PROLIA® (denosumab).
CONEXXENCE is a registered trademark of Fresenius Kabi Deutschland GmbH.
Other trademarks are the property of their respective owners.

* Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of CONEXXENCE has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.